CM
AVNS

Castleark Management’s Avanos Medical AVNS Stock Holding History

Castleark Management’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-243,107
Closed -$16.7M – 369
2018
Q3 		$16.7M Sell
243,107
-9,960
-4% -$641K 0.48% 67
2018
Q2 		$14.5M Buy
+253,067
New +$13.4M 0.45% 67

Other funds holding AVNS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Castleark Management's AVNS Position: Q4 2018 in Review

Castleark Management sold out of Avanos Medical (AVNS) in Q4 2018, closing a stake of 243,107 shares — an estimated $16.7M sold.

Castleark Management first reported a position in AVNS in Q2 2018 and held it in 2 quarters. The position peaked at $16.7M in Q3 2018. 350 funds tracked by Wall St. Rank hold AVNS as of Q4 2018.

  • Castleark Management reported no remaining Avanos Medical position as of Q4 2018 after selling out during the quarter.
  • Castleark Management sold 243,107 Avanos Medical shares in Q4 2018, an estimated $16.7M.
  • Castleark Management first reported a position in Avanos Medical in Q2 2018 and held it in 2 quarters.
  • Castleark Management's Avanos Medical position peaked at $16.7M in Q3 2018.
  • 350 funds tracked by Wall St. Rank held Avanos Medical as of Q4 2018.

Based on Castleark Management's 13F filing for Q4 2018, filed 12 Feb 2019.